Dateline City:
KENILWORTH, N.J.
Opinion Based on Findings from KEYNOTE-024 Trial, Which Showed Superior Overall Survival and Progression Free Survival with KEYTRUDA Compared to Chemotherapy
First Anti-PD-1 Therapy to Receive a CHMP Positive Opinion for Previously Untreated Patients with Metastatic NSCLC
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of KEYTRUDA (pembrolizumab), the
companys anti-PD-1 therapy, for the first-line treatment of metastatic
non-small cell lung cancer (NSCLC) in adults whose tumors have high
PD-L1 expression (tumor proportion score [TPS] of 50 percent or more)
with no EGFR or ALK positive tu
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
@Merck
read more